ESTRO 2025 - Abstract Book

S1802

Clinical – Upper GI

ESTRO 2025

( p =0.011). Twenty-two patients (79%) completed the full course of both radiotherapy and capecitabine. Overall, 16 patients (57%) experienced any type of grade ≥3 toxicity, which most commonly involved grade ≥3 dysphagia from treatment-related esophagitis (29%). Potentially capecitabine-related grade 5 toxicity was observed in 1 patient (4%), with death following duodenal perforation occurring outside the radiation field. Median PFS and OS were 8.8 and 11.2 months, respectively (Figure 2).